Hatemi, G. Et Al. 2021. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.. Clinical and experimental rheumatology , vol.39, no.5 , 80-87.

Hatemi, G., Mahr, A., Takeno, M., Kim, D. Y., Saadoun, D., Direskeneli, H., ... Melikoğlu, M.(2021). Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.. Clinical and experimental rheumatology , vol.39, no.5, 80-87.

Hatemi, Gülen Et Al. "Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.," Clinical and experimental rheumatology , vol.39, no.5, 80-87, 2021

Hatemi, Gülen Et Al. "Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.." Clinical and experimental rheumatology , vol.39, no.5, pp.80-87, 2021

Hatemi, G. Et Al. (2021) . "Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.." Clinical and experimental rheumatology , vol.39, no.5, pp.80-87.

@article{article, author={Gülen Hatemi Et Al. }, title={Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.}, journal={Clinical and experimental rheumatology}, year=2021, pages={80-87} }